ISSN: 1540-1405

Journal Home

Journal Guideline

Journal of the National Comprehensive Cancer Network : JNCCN Q1 Unclaimed

Harborside Press United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of the National Comprehensive Cancer Network : JNCCN is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 162. It has an SJR impact factor of 5,514 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 5,514.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Journal of the National Comprehensive Cancer Network : JNCCN

5,514

SJR Impact factor

162

H Index

159

Total Docs (Last Year)

609

Total Docs (3 years)

7107

Total Refs

6923

Total Cites (3 years)

514

Citable Docs (3 years)

11.49

Cites/Doc (2 years)

44.7

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

MMWR. Morbidity and mortality weekly report Q1
Annual Review of Public Health Q1
Annual Review of Clinical Psychology Q1
Journal of Thoracic Oncology Q1
Lancet Digital Health, The Q1

Compare this journals

Aims and Scope

Best articles by citations

VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision

HSR20-085: Real-World Study of Factors Associated With Breast Conserving Surgery for Females Diagnosed With Early Stage Breast Cancer

HSR20-087: Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List

HSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer

HSR20-090: Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review

HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia

HSR20-095: Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed With Small Cell Lung Cancer Who Received First-Line Systemic Therapy

HSR20-099: Cost Comparison of PARP Inhibitors in Women With Ovarian Cancer (OC) in the US HealthCare Market

HSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization

HSR20-101: Real-World Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study

HSR20-102: Quality Outcomes in Colon Cancer

The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care

SHOW MORE ARTICLES

The Process of NCCN Guidelines‚Ñ¢ Adaptation to the Middle East and North Africa Region

HSR20-103: Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016

HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study

HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network

HSR20-106: Quantifying Patient Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

HSR20-110: The Promotion of Exercise Oncology as a Standard Part of Clinical Practice

HSR20-111: Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis

HSR20-114: Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients With Hematologic Malignancies

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma